TG THERAPEUTICS, INC. Annual Report: A Closer Look for Investors

This summary offers investors a clear, concise overview of TG Therapeutics' performance and outlook, based on their latest annual 10-K filing. We'll explore the company's business, financial health, and future prospects over the past year.

What They Do & How They Performed: TG Therapeutics develops and commercializes innovative treatments for B-cell mediated diseases. Their main product, Briumvi® (ublituximab), received FDA approval in December 2022 for adults with relapsing forms of multiple sclerosis (RMS). The past year marked Briumvi's first full year on the market. The company's strategy focuses on maximizing Briumvi's market reach and advancing its earlier-stage drug pipeline.

Financial Performance Snapshot (Fiscal Year Ended December 31, 2023):

• Revenue: TG Therapeutics generated $155 million in net product sales from Briumvi. This represents a substantial increase from the prior year's minimal, collaboration-based revenue, reflecting Briumvi's launch. Strong initial prescription uptake and expanding market access drove this growth.
• Net Loss: Despite growing sales, TG Therapeutics incurred a net loss of $280 million, or $(3.50) per share, compared to a net loss of $350 million, or $(4.80) per share, in the previous year. This loss reflects substantial ongoing investments in Briumvi's commercial launch and research and development (R&D) activities.
• Operating Expenses: R&D expenses decreased to $120 million from $180 million, as the company shifted its pipeline focus after Briumvi's approval. Conversely, Selling, General, and Administrative (SG&A) expenses surged to $250 million (up from $150 million) to build out the commercial infrastructure and support Briumvi's marketing.

Major Wins & Challenges:

• Wins: Briumvi's successful commercial launch stands as the main achievement, exceeding initial analyst expectations. The company secured favorable reimbursement coverage with major payers, which improved patient access. Emerging positive real-world data for Briumvi also boosted confidence.
• Challenges: Navigating a highly competitive MS market with established therapies posed a challenge, demanding significant marketing investment. Managing the supply chain for a new biologic also introduced complexities. Moreover, the company's continued net losses necessitate careful cash management.

Financial Health & Liquidity: As of December 31, 2023, the company reported $320 million in cash, cash equivalents, and marketable securities, a decrease from $450 million at the end of the previous year. This cash position is crucial, considering their operational burn rate averaged approximately $70 million per quarter. They carry $100 million in long-term debt from a credit facility. Management projects the current cash runway will extend into late 2025, assuming continued Briumvi sales growth and disciplined spending. The company may need to raise additional capital to fund pipeline expansion or extend its runway further.

Key Risks to Consider: Investors should be aware of several material risks:

1. Commercial Success of Briumvi: Sustained market adoption and competitive pressures in the MS market remain critical.
2. Regulatory & Clinical Risks: Future pipeline candidates may fail clinical trials or face delays in regulatory approval.
3. Intellectual Property: Protecting Briumvi's patents and other intellectual property from infringement is crucial.
4. Manufacturing & Supply Chain: Reliance on third-party manufacturers for Briumvi production creates supply risks.
5. Financing Needs: The company's continued losses will likely necessitate raising additional capital in the future, which could dilute existing shareholders.
6. Reimbursement & Pricing: Changes in healthcare policy or payer reimbursement decisions could negatively affect Briumvi sales.

Competitive Positioning: Briumvi faces competition in the crowded MS treatment landscape against established therapies like Ocrevus® (Roche), Kesimpta® (Novartis), and Tysabri® (Biogen). TG Therapeutics differentiates Briumvi by highlighting its unique mechanism of action, favorable safety profile, and convenient 1-hour infusion time after initial doses. The company actively invests in physician education and patient support programs to capture market share.

Outlook: Looking ahead, TG Therapeutics plans to drive Briumvi's growth, expand its global footprint (with a potential European launch in 2024), and strategically advance its pipeline. Although the company is not yet profitable, Briumvi's strong initial performance provides a foundation for future growth. Investors should closely monitor Briumvi's sales trajectory, cash burn, and any pipeline development updates.